What is the Org number of EUROBIOLOGICAL AS?

EUROBIOLOGICAL AS is registered with Brønnøysundsregistrene under Org 929991451.

What is the revenue of EUROBIOLOGICAL AS?

EUROBIOLOGICAL AS reported revenue of NOK 37K in 2024.

Who is the CEO of EUROBIOLOGICAL AS?

Amr Ahmed Abdelrahim Gamil is Chief Executive Officer of EUROBIOLOGICAL AS, in role since 2022.

Who is the chairman of EUROBIOLOGICAL AS?

Cheng Xu chairs the board of EUROBIOLOGICAL AS, in role since 2022.

Where is EUROBIOLOGICAL AS headquartered?

EUROBIOLOGICAL AS's registered address is Johan Herman Wessels Vei 99, 1542 Vestby.

EUROBIOLOGICAL AS

ASActive

Org 929991451Johan Herman Wessels Vei 99, 1542 VestbyWholesale of pharmaceutical and medical goods · NACE 4646Est. 20220 employees

Revenue 2024

NOK 37K

+57% vs 2023

EBITDA margin

20.5%

+107% vs 2023

Equity ratio

-333.0%

Financial strength

Net profit 2024

NOK 8K

+107% vs 2023

EBITDA — year on yearNOK millions

Key figuresAnnual report 2024

Revenue	NOK 37K	+57%
EBITDA	NOK 8K	+107%
Net profit	NOK 8K	+107%
Total assets	NOK 30K	+939%
Equity	NOK -102K	+7%
Employees	0	—

Item	2022	2023	2024
Revenue	0	23	37
Staff expenses	−0	−0	−0
EBITDA	−32	−107	8
Depreciation & amort.	−0	−0	−0
EBIT	−32	−107	8
Net financials	0	0	0
Profit before tax	−32	−107	8
Tax	−0	−0	−0
Net profit	−32	−107	8

Item	2022	2023	2024
Total assets	18	3	30
Equity	−2	−109	−102
Long-term debt	0	0	0
Short-term debt	20	112	132
Total debt	20	112	132

Name	Role	Member since
Current (1)
AA Amr Ahmed Abdelrahim Gamil Chief Executive Officer	Chief Executive Officer	2022

Name	Role	Member since
Current (1)
CX Cheng Xu	Chairman	2022

Shareholder	Type	Ownership	Votes	Since
Unknown	Individual	50%	50%	2022

Person	Role here	Other companies
Amr Ahmed Abdelrahim Gamil	Chief Executive Officer	0 companies
Cheng Xu	Chairman	0 companies

EUROBIOLOGICAL AS

ASActive

Org 929991451Johan Herman Wessels Vei 99, 1542 VestbyWholesale of pharmaceutical and medical goods · NACE 4646Est. 20220 employees

Revenue 2024

NOK 37K

+57% vs 2023

EBITDA margin

20.5%

+107% vs 2023

Equity ratio

-333.0%

Financial strength

Net profit 2024

NOK 8K

+107% vs 2023

EBITDA — year on yearNOK millions

Key figuresAnnual report 2024

Revenue	NOK 37K	+57%
EBITDA	NOK 8K	+107%
Net profit	NOK 8K	+107%
Total assets	NOK 30K	+939%
Equity	NOK -102K	+7%
Employees	0	—